Next Article in Journal / Special Issue
Insurance Coverage Policies for Personalized Medicine
Previous Article in Journal / Special Issue
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy
Article

An Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective

1
Duke Translational Medicine Institute, Durham, NC 27715, USA
2
Department of Obstetrics & Gynecology, University of Virginia, Charlottesville, VA 22908, USA
3
Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC 27705, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2012, 2(4), 192-200; https://doi.org/10.3390/jpm2040192
Received: 3 September 2012 / Revised: 22 October 2012 / Accepted: 25 October 2012 / Published: 30 October 2012
Direct to consumer (DTC) genomic services facilitate the personalized and participatory aspects of “P4” medicine, but raise questions regarding use of genomic data in providing predictive and preventive healthcare. We illustrate the issues involved by describing a pregnancy management case in which a treatment plan was modified based on a DTC result. A woman whose personal and family history were otherwise unremarkable for thromboembolism learned through DTC testing about the presence of a prothrombin (factor 2) gene mutation (rs1799963). Twice daily injections of enoxaparin were recommended throughout pregnancy for this patient who, without prior knowledge of this mutation, would not have been offered such therapy. Moreover, genetically based medical guidelines are a moving target, and treatment of thrombophilic conditions in asymptomatic patients is controversial. We address the state of the art in actionable personalized medicine with respect to clotting disorders in pregnancy, as well as other factors at play— economics, patient preference, and clinical decision support. We also discuss what steps are needed to increase the utility of genomic data in personalized medicine by collecting information and converting it into actionable knowledge. View Full-Text
Keywords: personalized medicine; direct-to-consumer genetic testing; genetic counseling; thrombophilia; venous thromboembolism; clotting disorders; pregnancy personalized medicine; direct-to-consumer genetic testing; genetic counseling; thrombophilia; venous thromboembolism; clotting disorders; pregnancy
Show Figures

Figure 1

MDPI and ACS Style

Tenenbaum, J.D.; James, A.; Paulyson-Nuñez, K. An Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective. J. Pers. Med. 2012, 2, 192-200. https://doi.org/10.3390/jpm2040192

AMA Style

Tenenbaum JD, James A, Paulyson-Nuñez K. An Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective. Journal of Personalized Medicine. 2012; 2(4):192-200. https://doi.org/10.3390/jpm2040192

Chicago/Turabian Style

Tenenbaum, Jessica D., Andra James, and Kristin Paulyson-Nuñez. 2012. "An Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective" Journal of Personalized Medicine 2, no. 4: 192-200. https://doi.org/10.3390/jpm2040192

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop